Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

Also called NCT03371355

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 105 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03371355
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03371355. Randomized; triple masking; primary purpose treatment. Start 2017-12-21 (actual); primary completion 2019-11-21 (actual). Results posted on 2021-02-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
Condition
NAFLD
Condition
Diabetes Mellitus, Type 2
Condition
Hypertriglyceridemia
Condition
Fatty Liver, Nonalcoholic
Intervention (Drug)
Placebo
Intervention (Drug)
ISIS 703802 40 mg
Intervention (Drug)
ISIS 703802 80 mg
Intervention (Drug)
ISIS 703802 20 mg
Lead sponsor
Akcea Therapeutics (class: industry)
Collaborator
Ionis Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03371355
Content hash
121d2504390b2345013fff22b0ba6f4aea6630edeb9821629a7bd0861d7932e9